A clinical study of Ciforadenant
Latest Information Update: 12 Oct 2020
At a glance
- Drugs Ciforadenant (Primary)
- Indications Cancer; Multiple myeloma; Non-small cell lung cancer
- Focus Adverse reactions
- 12 Oct 2020 New trial record
- 05 Oct 2020 According to a Corvus Pharmaceuticals media release, the company has entered into a strategic collaboration with Angel Pharmaceuticals that will enable the development and commercialization of its pipeline of precisely targeted investigational medicines in China.
- 05 Oct 2020 According to a Corvus Pharmaceuticals media release, the company plan to initiate this study in the next 12 to 18 months